Realgar-Indigo naturalis Formulation clinical trials
How each study uses Realgar-Indigo naturalis Formulation is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Realgar-Indigo naturalis Formulation studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Realgar-Indigo Naturalis Formulation
- 2
Studies by the year they started
3 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2023 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 3
Peking University People's Hospital (1) · Instituto do Cancer do Estado de São Paulo (1) · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Realgar-Indigo naturalis Formulation is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical StudyNot yet recruitingPhase 4Peking University People's HospitalNCT07075250Written as Realgar-Indigo Naturalis Formulation Combined with Anlotinib
- Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic LeukemiaRecruitingPhase 2Instituto do Cancer do Estado de São PauloNCT06982274Written as Realgar-Indigo Naturalis Formulation
- Radiotherapy Combined With Realgar-Indigo Naturalis Formula (RIF) in the Treatment of Rhabdomyosarcoma(RMS) in ChildrenStatus unknownPhase 2Xinhua Hospital, Shanghai Jiao Tong University School of MedicineNCT05708391Written as Realgar-Indigo Naturalis Formulation